<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0">
   <channel>
      <title>Alta Partners</title>
      <link>http://www.altapartners.com/</link>
      <description>Alta Partners news.</description>
      <language>en</language>
      <copyright>Copyright 2006</copyright>
      <lastBuildDate>Wed, 01 Feb 2012 00:00:00 +0800</lastBuildDate>
      <generator>http://www.php.net/</generator>
      <docs>http://blogs.law.harvard.edu/tech/rss</docs> 
        
            <item>
         <title><![CDATA[Ablynx Receives Another Milestone as Boehringer Ingelheim Selects Nanobody® Candidate for Pre-Clinical Development]]></title>
         <description><![CDATA[
    <p><a href='http://hugin.info/137912/R/1581931/494165.pdf'>http://hugin.info/137912/R/1581931/494165.pdf</a></p> 
        ]]></description>
         <link>http://hugin.info/137912/R/1581931/494165.pdf</link>
         <guid>http://hugin.info/137912/R/1581931/494165.pdf</guid>
         <pubDate>Wed, 01 Feb 2012 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Wills Hughes-Wilson appointed Vice President Government Affairs & Policy - Swedish Orphan Biovitrum]]></title>
         <description><![CDATA[
    <p><a href='http://hugin.info/134557/R/1581289/493869.pdf'>http://hugin.info/134557/R/1581289/493869.pdf</a></p> 
        ]]></description>
         <link>http://hugin.info/134557/R/1581289/493869.pdf</link>
         <guid>http://hugin.info/134557/R/1581289/493869.pdf</guid>
         <pubDate>Tue, 31 Jan 2012 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[AcelRx Announces its ARX-01 Phase 3 Program Expected to Start Late Q1 or Early Q2 2012]]></title>
         <description><![CDATA[
    <p><a href='http://news.acelrx.com/phoenix.zhtml?c=241441&p=RssLanding&cat=news&id=1654513'>http://news.acelrx.com/phoenix.zhtml?c=241441&p=RssLanding&cat=news&id=1654513</a></p> 
        ]]></description>
         <link>http://news.acelrx.com/phoenix.zhtml?c=241441&amp;p=RssLanding&amp;cat=news&amp;id=1654513</link>
         <guid>http://news.acelrx.com/phoenix.zhtml?c=241441&amp;p=RssLanding&amp;cat=news&amp;id=1654513</guid>
         <pubDate>Tue, 31 Jan 2012 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Novel Immune Regulation Mechanism Involving Natural Killer Cells Described and Published in "Science" Magazine by a Key Academic Partner of Innate Pharma]]></title>
         <description><![CDATA[
    <p><a href='http://www.innate-pharma.com/node/977'>http://www.innate-pharma.com/node/977</a></p> 
        ]]></description>
         <link>http://www.innate-pharma.com/node/977</link>
         <guid>http://www.innate-pharma.com/node/977</guid>
         <pubDate>Fri, 20 Jan 2012 00:00:00 +0800</pubDate>
      </item>
        
            <item>
         <title><![CDATA[Pathwork Diagnostics: Cancer Patients Experience Increased Survival Time After Pathwork Tissue of Origin Test]]></title>
         <description><![CDATA[
    <p><a href='http://www.pathworkdx.com/news/cancer_patients_experience_increased_survival_time_after_pathwork_tiss5'>http://www.pathworkdx.com/news/cancer_patients_experience_increased_survival_time_after_pathwork_tiss5</a></p> 
        ]]></description>
         <link>http://www.pathworkdx.com/news/cancer_patients_experience_increased_survival_time_after_pathwork_tiss5</link>
         <guid>http://www.pathworkdx.com/news/cancer_patients_experience_increased_survival_time_after_pathwork_tiss5</guid>
         <pubDate>Thu, 19 Jan 2012 00:00:00 +0800</pubDate>
      </item>
 
  </channel>
</rss>
     
